Delcath Systems, Inc. DCTH R2K
Healthcare · Medical Devices · United States
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
READ MORE ›$10.78
-33.50% 1Y
Market & Price
Market Cap
$372.14M
Current Price
$10.78
High / Low (52W)
$16.87 / $8.19
Beta
0.54
Valuation
Stock P/E
1,078.00
Industry PE
23.65
Forward P/E
-
PEG Ratio
1.60
Book Value
$3.27
Price to Book
3.30
P/S
4.11
EV/EBITDA
-214.64
Dividend Yield
-
Profitability & Returns
ROCE
0.59%
ROE
0.58%
ROA
-0.95%
Profit Margin
0.62%
Op Margin
-6.55%
EPS (Latest Qtr)
$-0.03
EPS (TTM)
$0.01
Balance Sheet & Liquidity
Debt/Equity
0.81
Quick Ratio
9.72
Current Ratio
11.24
Debt
$907.00K
Total Assets
$123.63M
Current Assets
$119.53M
Working Capital
$108.58M
Ownership
Promoter Holding
8.13%
Chg in Prom Hold
-
FII / Inst Holding
48.80%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$283.75M
Total Revenue (TTM)
$90.44M
EBITDA
$-1.32M
Free Cash Flow
$19.65M
Operating Cash Flow
$21.17M
Shares Outstanding
34.52M
Gross Margin
85.97%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
215.30%
Profit 5Y
35.80%
Revenue (YoY)
26.30%
Earnings (YoY)
-
PROS
- Compounding revenue at 215.3% over 5 years.
- Profit CAGR of 35.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 1078.0.
- Trading 36.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DCTH Delcath Systems, Inc. R2K | 10.78 | 1,078.00 | $372.14M | - | 0.59% | 0.58% | 215.30% | 35.80% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 584.00K | 684.00K | - | - | 858.00K | 824.00K | - | - | - | - | - | - | - | - | - | 378.00K | 797.00K | 906.00K | 597.00K | 495.00K | 434.00K | 3.14M | 7.77M | - | - | 19.78M | 24.16M | 20.56M | 20.73M | 24.99M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.85M | 3.32M | 2.62M | 3.01M | 3.74M |
| Gross Profit | - | 311.00K | 329.00K | 309.00K | - | 259.00K | 361.00K | 323.00K | - | 524.00K | 449.00K | 512.00K | - | 555.00K | 638.00K | 591.00K | 174.00K | 240.00K | 208.00K | 216.00K | 211.00K | 278.00K | 276.00K | 334.00K | 295.00K | 345.00K | 617.00K | 671.00K | 416.00K | 345.00K | 301.00K | 2.24M | 6.25M | - | - | 16.94M | 20.84M | 17.94M | 17.72M | 21.26M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.30M | 18.25M | 18.33M | 19.90M | 22.89M |
| Operating Income | -3.29M | -3.71M | -3.62M | -3.65M | -4.23M | -3.46M | -3.87M | -4.72M | -4.38M | -4.21M | -4.60M | -4.63M | -4.72M | -7.50M | -6.09M | -5.79M | -5.67M | -4.13M | -5.57M | -5.07M | -4.27M | -4.98M | -6.73M | -6.45M | -6.70M | -8.34M | -9.49M | -8.17M | -8.32M | -8.00M | -10.56M | -10.28M | -3.91M | - | - | 642.00K | 2.59M | -388.00K | -2.18M | -1.64M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 709.00K | 2.62M | -242.00K | -2.08M | -1.51M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.26M | 3.21M | 375.00K | -1.33M | -908.00K |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 195.00K | 508.00K | -455.00K | 562.00K | 162.00K |
| Net Income | -2.94M | -3.49M | -3.70M | -2.42M | -5.09M | -1.81M | -6.67M | -1.00M | -8.49M | -11.33M | -1.94M | -12.60M | -19.25M | 7.18M | -6.66M | -8.88M | -7.89M | -5.96M | -7.52M | -7.86M | -4.28M | -4.99M | -6.75M | -6.43M | -7.12M | -9.00M | -10.16M | -8.88M | -9.00M | -7.20M | -20.34M | -11.11M | -13.74M | - | - | 1.07M | 2.70M | 830.00K | -1.90M | -1.07M |
| Diluted EPS | -0.31 | - | -0.30 | - | - | - | -4.41 | - | - | -45,695.00 | -1,373.00 | -4,565.00 | - | 10.91 | -7.26 | -0.25 | -75.11 | -58.50 | -73.82 | -108.07 | -1.90 | -1.16 | -1.04 | -0.96 | -0.94 | -1.10 | -1.24 | -0.96 | -0.77 | -0.58 | -1.14 | -0.45 | -0.48 | - | - | 0.03 | 0.07 | 0.02 | -0.05 | -0.03 |
| R&D Expense | - | 979.00K | 1.45M | 1.68M | - | 1.34M | 1.95M | 2.69M | - | 2.32M | 2.52M | 2.28M | - | 5.69M | 4.09M | 4.11M | 3.30M | 1.71M | 1.78M | 2.97M | 2.22M | 3.26M | 3.71M | 3.50M | 2.96M | 4.48M | 5.61M | 4.07M | 4.58M | 3.56M | 4.66M | 3.70M | 3.39M | 3.87M | - | 5.01M | 6.88M | 7.99M | - | 9.82M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.72M | 2.06M | 37.20M | 85.23M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 686.00K | 635.00K | 6.19M | 11.80M |
| Gross Profit | - | 0 | 0 | 307.00K | 326.00K | 778.00K | 1.28M | 1.44M | 2.01M | 2.40M | 861.00K | 1.01M | - | 2.03M | 1.43M | 31.02M | 73.43M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 35.89M | 39.61M | 43.43M | 72.77M |
| Operating Income | -13.54M | -30.74M | -46.46M | -53.87M | -33.02M | -19.30M | -15.21M | -16.44M | -18.16M | -27.07M | -19.91M | -21.30M | - | -33.85M | -38.18M | -12.41M | 660.00K |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -33.69M | -37.78M | -12.18M | 1.01M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 1.19M | 2.69M | 1.44M | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -36.51M | -47.68M | -26.39M | 3.51M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 810.00K |
| Net Income | -22.06M | -46.68M | -30.89M | -51.87M | -30.32M | -17.38M | -14.70M | -17.97M | -45.12M | -19.22M | -8.88M | -24.16M | - | -36.51M | -47.68M | -26.39M | 2.70M |
| Diluted EPS | - | - | -0.68 | -13.54 | -5.10 | -1.84 | -0.91 | - | -3,250.00 | -0.72 | -342.83 | -8.35 | - | -4.12 | -2.94 | -0.93 | 0.07 |
| R&D Expense | 9.64M | 17.56M | 25.17M | 26.21M | 12.69M | 4.30M | 6.49M | 8.45M | 10.49M | 19.65M | 9.49M | 11.20M | 13.78M | 18.58M | 17.50M | 13.87M | 29.25M |
Compounded Sales Growth
| 5 Years: | 215.30% |
| 1 Year: | 26.30% |
Compounded Profit Growth
| 5 Years: | 35.80% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -33.50% |
| 6 Months: | +16.79% |
| 3 Months: | +21.12% |
| 1 Month: | +5.58% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Aug 1988 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 50.58M | 35.24M | 30.47M | 37.10M | 23.76M | 15.73M | 35.24M | 8.89M | 6.84M | 14.21M | 34.63M | - | 17.86M | 38.61M | 76.59M | 123.63M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.16M | 37.16M | 73.76M | 119.53M |
| Cash & Equivalents | 0 | 6.94M | 35.49M | 45.62M | 25.78M | 23.73M | 31.25M | 20.47M | 12.61M | 4.41M | 4.00M | 2.52M | 10.00M | 28.57M | - | 7.67M | 12.65M | 32.41M | 43.45M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.00M | 3.32M | 6.93M | 10.25M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 366.00K | 241.00K | 10.89M | 11.74M |
| Total Liabilities | - | - | - | - | - | - | - | 5.62M | 7.13M | 36.73M | 8.21M | 21.78M | 20.57M | 12.56M | - | 23.72M | 22.84M | 7.84M | 12.41M |
| Current Liabilities | - | - | - | 21.20M | 8.84M | 10.16M | 6.63M | 4.58M | 6.31M | 36.09M | 7.81M | 17.75M | 15.99M | 10.04M | - | 14.73M | 16.45M | 6.14M | 10.95M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.01M | 7.84M | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.87M | 10.19M | 1.04M | 936.00K |
| Total Equity | 0 | 10.21M | 23.76M | 29.08M | 26.10M | 20.01M | 30.10M | 18.14M | 8.60M | -1.49M | 678.00K | -14.94M | -6.36M | 22.08M | - | -5.86M | 15.78M | 68.75M | 111.22M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.05M | 22.76M | 33.06M | 34.69M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.46M | -24.08M | -37.37M | -50.01M | -34.10M | - | - | - | -15.40M | -14.73M | -23.69M | -22.87M | - | -24.95M | -31.25M | -18.68M | 22.52M |
| Investing Cash Flow | 3.53M | -3.13M | -6.09M | 2.86M | -142.00K | - | - | - | -524.00K | -76.00K | -24.00K | -782.00K | - | -209.00K | -19.71M | -981.00K | -26.59M |
| Financing Cash Flow | 35.48M | 37.35M | 23.62M | 45.06M | 41.70M | - | - | - | -10.52M | 13.24M | 30.30M | 42.35M | - | 10.14M | 51.78M | 39.41M | 15.05M |
| Capital Expenditure | -515.00K | -1.64M | -2.61M | -2.12M | -142.00K | -44.00K | -170.00K | -258.00K | -524.00K | -76.00K | -24.00K | -782.00K | - | -209.00K | -58.00K | -559.00K | -1.55M |
| Free Cash Flow | -10.98M | -25.72M | -39.98M | -52.13M | -34.24M | - | - | - | -15.92M | -14.81M | -23.71M | -23.65M | - | -25.16M | -31.31M | -19.24M | 20.97M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.02M | 818.00K | 19.75M | 10.97M |
| Share Buybacks | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 6.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | 74.8% | 69.2% | 83.4% | 86.2% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | -1,245.1% | -1,849.0% | -33.4% | 0.8% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | -1,342.7% | -2,308.9% | -70.9% | 3.2% |
| ROE % | -92.8% | -160.5% | -118.3% | -259.2% | -100.7% | -95.8% | -171.0% | 1,206.1% | -6,654.4% | 128.7% | 139.7% | -109.4% | - | 623.1% | -302.2% | -38.4% | 2.4% |
| ROCE % | - | -104.6% | -175.9% | -265.1% | -108.4% | -100.6% | -161.4% | 1,920.6% | -1,692.9% | 248.2% | 1,117.2% | -86.6% | - | -1,082.6% | -172.3% | -17.6% | 0.6% |
Shareholding Pattern
Insiders
8.13%
Institutions
48.80%
Public Float
53.11%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | - | 1.33M | $14.33M |
| 2 | Blackrock Inc. | - | 1.78M | $19.24M |
| 3 | Private Wealth Advisors, LLC | - | 591.52K | $6.38M |
| 4 | Rosalind Advisors, Inc. | - | 3.30M | $35.58M |
| 5 | Propel Bio Management, LLC | - | 979.70K | $10.56M |
| 6 | Geode Capital Management, LLC | - | 692.03K | $7.46M |
| 7 | State Street Corporation | - | 664.43K | $7.16M |
| 8 | Millennium Management Llc | - | 588.05K | $6.34M |
| 9 | Divisadero Street Capital Management, LP | - | 499.80K | $5.39M |
| 10 | Ikarian Capital, LLC | - | 431.25K | $4.65M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DCTH
No recent headlines available.